SRZN - שווי פעילות לרווח לפני ריבית, מסים ופחת Surrozen

Surrozen, Inc. (SRZN) minimizes biomedical threats by developing means for gut and liver regeneration through selective cell activation. Business growth relies on internal clinical trial cycles, which offsets the impact of the external economy. The company's high authority is based on the development of antibodies for tissue restoration. The current EV/EBITDA ratio on GURU.Markets is 0.00, which is reflected in the asset value chart.

For the biopharmaceutical business of Surrozen, Inc. (SRZN), which combines AI automation with capital-intensive medical oversight, assessing asset value relative to operating cash flow is critical. By analyzing the EV/EBITDA multiple—accounting for operating profit and amortization—an investor compares market capitalization and debt against actual production efficiency to determine whether the current price is undervalued or excessive.